Antibody-Mediated Lung Transplant Rejection

Area of Science:

• Immunology
• Transplantation Medicine
• Pulmonary Medicine

Background:

• Antibody-mediated rejection (AMR) is a complex complication following lung transplantation.
• Emerging evidence implicates humoral immunity and donor-specific antibodies (DSAs) in allograft rejection.
• DSAs are associated with acute cellular rejection and bronchiolitis obliterans syndrome.

Purpose of the Study:

• To review the current understanding of antibody-mediated rejection in lung transplantation.
• To highlight the role of humoral immunity and donor-specific antibodies.
• To underscore the need for further research into the incidence and impact of AMR.

Main Methods:

• Literature review of recent studies on antibody-mediated rejection in lung transplantation.
• Analysis of evidence linking donor-specific antibodies to transplant outcomes.
• Discussion of clinical cases illustrating antibody-mediated injury.

Main Results:

• Donor-specific antibodies are an independent risk factor for acute cellular rejection and bronchiolitis obliterans syndrome.
• Antibodies can directly cause severe allograft dysfunction and injury.
• The exact incidence and impact of AMR are currently unknown due to diagnostic challenges.

Conclusions:

• Humoral immunity plays a critical role in lung allograft rejection.
• Further research and a standardized definition are needed to accurately assess and manage antibody-mediated rejection.
• Clinical investigation into humoral immunity is crucial for improving lung transplant outcomes.